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methotrexate on TLR signaling during intestinal
chemotherapy-induced mucositis in a rat
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and Drora Berkowitz4Abstract
Toll-like receptor 4 (TLR-4) is crucial in maintaining intestinal epithelial homeostasis, participates in a vigorous
signaling process and heightens inflammatory cytokine output. The objective of this study was to determine the
effects of glutamine (GLN) on TLR-4 signaling in intestinal mucosa during methotrexate (MTX)-induced mucositis
in a rat. Male Sprague–Dawley rats were randomly assigned to one of four experimental groups of 8 rats each:
1) control rats; 2) CONTR-GLN animals were treated with oral glutamine given in drinking water (2%) 48 hours before
and 72 hours following vehicle injection; 3) MTX-rats were treated with a single IP injection of MTX (20 mg/kg);
and 4) MTX-GLN rats were pre-treated with oral glutamine similar to group B, 48 hours before and 72 hours after
MTX injection. Intestinal mucosal damage, mucosal structural changes, enterocyte proliferation and enterocyte
apoptosis were determined 72 hours following MTX injection. The expression of TLR-4, MyD88 and TRAF6 in the intestinal
mucosa was determined using real time PCR, Western blot and immunohistochemistry. MTX-GLN rats demonstrated a
greater jejunal and ileal mucosal weight and mucosal DNA, greater villus height in ileum and crypt depth and
index of proliferation in jejunum and ileum, compared to MTX animals. The expression of TLR-4 and MyD88
mRNA and protein in the mucosa was significantly lower in MTX rats versus controls animals. The administration
of GLN increased significantly the expression of TLR-4 and MyD88 (vs the MTX group). In conclusion, treatment
with glutamine was associated with up-regulation of TLR-4 and MyD88 expression and a concomitant decrease in
intestinal mucosal injury caused by MTX-induced mucositis in a rat.
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The family of mammalian Toll-like receptors (TLRs) are
homologs of the Drosophila Toll protein, which was ori-
ginally identified as a receptor that plays a central role in
the establishment of the embryonic dorsal-ventral pattern
in fly embryos [1]. Growing evidence suggests that TLRs
have a critical role in the recognition of bacterial lipopro-
teins, major components of bacterial cell walls. Their sig-
naling pathway is known to activate target genes such as
nuclear factor-κB (NF-κB) and cytokines that are involved* Correspondence: igor-dr@internet-zahav.net
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unless otherwise stated.in inflammation and immune responses [2-4]. In 1997,
Medzhitov et al. demonstrated that a Toll-like receptor
now known as TLR4 could, when artificially ligated using
antibodies, induce the activation of certain genes neces-
sary for initiating an adaptive immune response [5]. When
activated, TLRs recruit adapter molecules within the cyto-
plasm of cells in order to propagate a signal. Four adapter
molecules are known to be involved in signaling. These
proteins are known as myeloid differentiation primary re-
sponse gene-88 (MyD88), Mal/TIRAP (Mal is also called
TIR domain-containing adaptor protein [TIRAP]), TIR
domain-containing adaptor-inducing interferon-β (TRIF)
and TRIF-related adaptor molecule (TRAM) interacting
with TLRs in response to ligand stimulation. When en-
gaged by gram-negative lipopolysaccharide (LPS), this
complex transduces a signal detected by MyD88, which isral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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kinase (IRAKs), receptor-associated factor 6 (TRAF6), and
NF-kappa B inducing kinase (NIK), resulting in activation
of NFκB which amplifies the signal, and ultimately leads
to the induction or suppression of genes that orchestrate
the inflammatory response [2,4].
Recent studies have shown that there is an overexpres-
sion of TLR2 and TLR4 in intestinal epithelial cells
which is correlated with the severity of mucosal damage,
together with an increase of apoptotic cells and mark-
edly impaired proliferation [5]. The increased expression
of TLRs was found in the intestinal tissues during ex-
perimental necrotizing enterocolitis (NEC) which is a
well known pediatric intestinal inflammatory disease [6].
TLRs when activated by bacterial ligands signal intracel-
lularly to up-regulate the expression of various cytokines
in the intestine, including pro-(IL-1β, IL-6, IL-8) and
anti-inflammatory cytokines (IL-10) in human and dif-
ferent NEC models [7,8].
Oral and gastrointestinal mucositises are common
complications of chemotherapy, in particular with drugs
affecting DNA synthesis (S-phase-specific agents such as
fluorouracil, methotrexate, and cytarabine). Mucositis
occurs in 40% of patients after standard dose chemo-
therapy, and in 100% of patients undergoing high dose
chemotherapy and stem cell or bone marrow transplant-
ation and contributes not only to the morbidity of treat-
ment but also to its cost [9,10]. The pathogenesis of
chemotherapy induced gastrointestinal mucositis has
been described by Sonis et al. [11] and includes five
phases: initiation by chemotherapy, up-regulation and
generation of messenger signals, signaling by pro-
inflammatory cytokines and amplification of mucosal
injury, ulceration of the mucosa and finally, healing.
The initial stages of inflammation in mucositis include
increased pro-inflammatory cytokine levels, which act
as a homing marker for inflammatory immune cells in
the submucosa.
Glutamine is a nonessential amino acid which is bene-
ficial in the prevention of infectious morbidity and mor-
tality in seriously ill patients, in part due to its ability to
maintain the integrity of intestinal mucosal epithelium.
Extensive studies in various experimental models have
established that glutamine is an essential respiratory sub-
strate for cells in the small intestinal mucosa, accounting
for over one-third of the total CO2 produced in the
small intestine [12]. While in the large bowel the short
chain fatty acid butyrate is the preferred fuel for the co-
lonic mucosa, many experimental studies have indicated
that glutamine is the preferred fuel source for the small
intestine [13,14]. In addition, glutamine exerts a positive
effect on the gut-associated lymphoid tissue and en-
hances gut barrier function. We have demonstrated re-
cently that administration of enteral glutamine preventsintestinal mucosal damage and accelerates intestinal re-
covery following methotrexate-induced mucositis in a
rat [15]. In this study, we showed that treatment with
glutamine attenuates alterations in TLR-4, MyD88 and
TRAF6 intestinal expression during LPS endotoxemia in
a rat [16].
In the current study we hypothesized that TLR signaling
may be involved in the development of MTX-induced in-
testinal mucositis and that treatment with glutamine
might reduce the alterations in this pathway.
Methods
Animals
This experiment and animal care were conducted in
compliance with the guidelines established by the “Guide
for the Care and Use of Laboratory Animals”, Rappaport
Faculty of Medicine, Technion (Haifa, Israel). Male
Sprague–Dawley rats (250-300 g) were used in this
study. Animals were housed in wire-bottomed cages
and were acclimatized at 21°C on 12:12-h light–dark
cycle for a minimum of five days before the experi-
ment. The rats were allowed access to water and chow
ad libitum.
Experimental design
Animals were randomly assigned to one of four experi-
mental groups of 8 rats each: 1) control rats (Group A)
underwent IP injection of sterile saline (CONTR); 2)
Group B (CONTR-GLN) animals were treated with oral
glutamine given in drinking water (2%) 48 hours before
and 72 hours following vehicle injection; 3) Group C rats
(MTX) were treated with a single IP injection of MTX
(20 mg/kg); and 4) Group D (MTX-GLN) were pre-
treated with oral glutamine given similar to group B rats,
48 hours before and 72 hours after MTX injection.
Intestinal mucosal parameters
Three days following MTX or vehicle injection, animals
were anesthetized with IP sodium pentobarbital (75 mg/kg)
and were sacrificed by open pneumothorax. The small
bowel was excised quickly, washed with cold isotonic saline
and divided into two segments: proximal jejunum and ter-
minal ileum. Each segment was weighed and cut longitu-
dinally. Mucosa was scraped using a glass slide, collected
and weighed. Total RNA, DNA and protein from the je-
junum and ileum were extracted sequentially as described
by Chomczynski [17]. Quantitization of DNA was per-
formed by spectrophotometry using A260 value (one A260
unit equals 50 μg of double-stranded DNA) and calculated
as μg/cm bowel length/100 g body weight.
Histological examination
Tissue samples were removed from the jejunum and
ileum and were immediately fixed in 4% neutral-buffered
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and sectioned. Deparaffinized 5 μm sections were stained
with haematoxylin and eosin. The mucosal damage of the
small bowel was graded using an intestinal injury score as
described by Kesik et al. [18]. The following parameters
were investigated in the jejunum and ileum: (1) degener-
ation of surface and crypt epithelium, (2) degeneration of
villus structure and vacuolization in the surface epithe-
lium, and (3) inflammatory cell infiltration and bleeding
and edema in the lamina propria. For each parameter, a
score was given using a semiquantitative scale as follows:
0 = none, 1 =mild, 2 =moderate, 3 = severe, giving a max-
imum possible score of 9 for each intestinal region.
The villus height and crypt depth for each specimen
were measured using an objective mounted micrometer
(100 × magnification) and an optical microscope (10 ×
100 magnification). Villus height and crypt depth data
were taken from eight rats, and each measurement con-
sisted of the mean of ten villi and crypts.Enterocyte proliferation and apoptosis
Crypt cell proliferation was assessed using 5-
bromodeoxyuridine (5-BrdU). Standard BrdU labeling
reagent (Zymed Laboratories, Inc, San Francisco, CA)
was injected intraperitoneally at a concentration of
1 ml/100 g body weight 2 hours before sacrifice. Tissue
slices (5 μm) were stained with a biotinylated monoclo-
nal anti-BrdU antibody system provided in a kit form
(Zymed Laboratories, Inc, San Francisco, CA). An
index of proliferation was determined as the ratio of
crypt cells staining positively for BrdU per 10 crypts.
Additional 5 μm thick sections were prepared to estab-
lish the degree of enterocyte apoptosis. Immunohisto-
chemistry for Caspase-3 (Caspase-3 cleaved concentrated
polyclonal antibody; dilution 1:100; Biocare Medical,
Walnut Greek, CA) was performed for identification of
apoptotic cells using a combination of the streptovidin-
biotin-peroxidase method and microwave antigen retrieval
on formalin-fixed, paraffin-embedded tissues according to
the manufacturer’s protocols. The apoptotic index (AI)
was defined as the number of apoptotic cells per 10 villi.
A qualified pathologist blinded as to the source of in-
testinal tissue performed all measurements.TLR4, MyD88 and TRAF6 mRNA expression (Real time
PCR analysis)
Expression of TLR4, MyD88 and TRAF6 mRNA levels
was determined by quantitative real-time PCR (7500
Real-Time PCR System, Applied Biosystems, USA) on
cDNA samples using Cyber Green Master Mix (ROVA-
LAB, Germany) with the exception of template and
primers. Primers for Rattus norvegicus TLR4, MyD88
and TRAF6 were synthesized by Syntezza Bioscience ltd.Israel, and 18 s rRNA Control kit from Eurogentec, EGT
Group.
Western blot analysis
Tissue was homogenized in RIPA lysis buffer containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP-40,
2 mM EDTA, supplemented with a cocktail of protease
and phosphatase inhibitors. Protein concentrations were
determined by Bradford reagent according to the manu-
facturer’s instructions. Samples containing equal amounts
of total protein (30 μg) were resolved by SDS-PAGE under
reducing conditions. After electrophoresis, proteins were
transferred to a PVDF membrane and probed with various
primary antibodies to anti-TLR-4 antibody (1:100 dilu-
tion), anti-MyD88 antibody (1:200 dilution) and anti-
ERK antibody (1:1000 dilution, sc-56899). Horseradish
peroxidase-conjugated secondary antibody was purchased
from Jackson ImmunoResearch Laboratories Inc. (West
Grove, PA) and an enhanced chemiluminescent substrate
from Biological Industries (Kibbutz Beth HaEmek, Israel).
The optical density of the specific protein bands was
quantified by using a densitometer (Vilber Lourmat,
Lyons, France).
Immunohistochemistry for TLR-4 and TRAF6 expression
Immunohistochemistry for TLR-4 and TRAF6 (TLR-4
polyclonal antibody; dilution 1:100, Santa Cruz,CA and
TRAF6 polyclonal antibody; dilution 1:100, Santa Cruz,
CA) was performed to identify TLR-4 and TRAF6 ex-
pression, using a combination of streptovidin-biotin-
peroxidase method according to manufacturers’ proto-
cols. The paraffin-embedded sections were de-waxed
and rehydrated with xylene and graded alcohol. Tissue
sections were microwave-pretreated in 10 mM EDTA
buffer and incubated with an endogenous peroxidase
(3%) in methanol for 10 minutes. After incubation with
blocking solution at room temperature for 10 minutes,
the sections were then incubated with TLR-4 and
TRAF6 concentrated polyclonal antibody for 60 minutes
and second human-absorbed, biotinylated, affinity-purified
antibody for 20 minutes. TLR-4 and TRAF6 receptor posi-
tive color development was obtained by incubating the
sections with DAB (Deoxyaminobenzidine) substrate
(Zymed Laboratories). A qualified pathologist blinded
as to the source of the intestinal tissue performed all
measurements.
Statistical analysis
The data are expressed as the mean ± SEM. A one-way
ANOVA for comparison, followed by Tukey’s test for
pair-wise comparison was used for statistical analysis.
Prism software was used (GraphPad Software, Inc., San
Diego, CA) and statistical significance was defined as
P < 0.05.
Sukhotnik et al. Nutrition & Metabolism 2014, 11:17 Page 4 of 11
http://www.nutritionandmetabolism.com/content/11/1/17Results
Intestinal mucosal parameters
MTX-induced intestinal damage (Group C) resulted in
a significant decrease in bowel weight in jejunum (10%,
p < 0.05) and ileum (12%, p < 0.05), mucosal weight in
jejunum (29%, p < 0.05), and ileum (20%), mucosal DNA
in jejunum (three-fold decrease, p < 0.05), and ileum
(30%, p < 0.05), and mucosal protein in jejunum (18%,
p < 0.05), and ileum (22%, p < 0.05) compared to control
animals (Group A) (Table 1). Following oral glutamine
administration, MTX-rats (Group D) demonstrated a
significant increase in ileal bowel weight (11%, p < 0.05),
jejunal (19%, p < 0.05) and ileal (27%, p < 0.05) mucosal
weights, and jejunal (23%, p < 0.05) and ileal (29%, p <
0.05) protein content compared to MTX-untreated an-
imals (Group C).Histological changes
Administration of GLN in control animals (Group B)
had no significant effect on the semi-quantitative dam-
age score compared to control rats (Group A) (Figure 1).
MTX-animals histologically exhibited a significant loss
of crypt architecture and signs of crypt remodeling,
severe villous epithelial atrophy, degeneration and short-
ening of the villus length, and polymorphonuclear
leukocyte infiltration in the lamina propria. Histological
damage was initially assessed in jejunum and ileum by
the semi-quantitative score, which included three criteria
that were markedly affected by methotrexate. Intestinal
damage as a result of methotrexate administration was
greatest in the distal ileum (7.5 ± 0.3 vs 1.6 ± 0.3, p < 0.001)
and was less significant in the proximal jejunum (5.6 ± 0.5
vs 1.5 ± 0.02, p < 0.001). Treatment of MTX rats with en-
teral GLN (Group D) resulted in a significant decrease inTable 1 Effect of MTX and glutamine on intestinal mucosal pa
Paramaters/Groups CONTR
Bowel weight (mg/cm/100 g BW)
Jejunum 22.6 ± 0.9
Ileum 20.0 ± 0.9
Mucosal weight (mg/cm/100 g BW)
Jejunum 9.7 ± 0.6
Ileum 9.0 ± 0.5
Mucosal DNA (μg/cm/100 g BW)
Jejunum 4.5 ± 0.4
Ileum 7.4 ± 0.8
Mucosal protein (μg/cm/100 g BW)
Jejunum 160 ± 13
Ileum 166 ± 8
CONTR-control, GLN-glutamine, MTX-methotrexate.
*P < 0.05 vs control, †P < 0.05 MTX-GLN vs MTX.the intestinal damage score in the distal ileum (4.7 ± 0.7 vs
7.5 ± 0.3, p < 0.001) compared to MTX-animals (Group C).
MTX-rats (Group C) showed a significant decrease (vs
control animals, Group A) in villus height in jejunum (two-
fold decrease, p < 0.05) and ileum (37% decrease, p < 0.05)
as well as crypt depth in jejunum (43% decrease, p < 0.05)
and ileum (34% decrease, p < 0.05) compared to control an-
imals (Group A) (Table 2). MTX-GLN rats (Group D) dem-
onstrated a significantly greater villus height in jejunum
(14% increase, p < 0.05) and ileum (32% increase, p < 0.05),
as well as crypt depth in jejunum (34% increase, p < 0.05)
and ileum (33% increase, p < 0.05) compared to MTX-
untreated animals (Group C).
Enterocyte proliferation and apoptosis
MTX rats (Group B) demonstrated a significant decrease
in the rate of enterocyte proliferation in both jejunum
(16% decrease, p < 0.01) and ileum (21% decrease, p < 0.05)
and a concomitant increase in the apoptotic index in je-
junum (two-fold, p < 0.05) and ileum (five-fold, p < 0.05)
compared to control animals (Table 2). Treatment with
oral glutamine (Group D) led to a significant increase in
the enterocyte proliferation rate in jejunum (11% increase,
p < 0.05) and ileum (18% increase, p = 0.001), and a con-
comitant decrease in the enterocyte apoptosis in ileum
(42% decrease, p < 0.05) compared to MTX-animals
(Group C).
TLR-4, MyD88 and TRAF6 mRNA expression
MTX rats (Group C) showed a significant decrease in
TLR-4 mRNA expression in jejunum (two-fold decrease,
p < 0.05), MyD88 mRNA expression in jejunum (15-fold
decrease, p < 0.05) and ileum (four-fold decrease, p < 0.05),
and TRAF6 mRNA expression in jejunum (10-fold de-
crease, p < 0.05) and ileum (37% decrease, p < 0.05)rameters
CONTR-GLN MTX MTX-GLN
21.3 ± 0.5 20.3 ± 0.4* 19.7 ± 1.3
19.0 ± 0.8 18.3 ± 0.8* 20.3 ± 1.1†
10.1 ± 0.6 6.9 ± 0.5* 8.2 ± 0.6*†
8.4 ± 0.3 7.2 ± 0.2* 9.1 ± 0.7†
4.2 ± 1.4 1.6 ± 0.4* 1.6 ± 0.2*
5.5 ± 1.5 5.2 ± 0.5* 5.2 ± 0.6*
184 ± 30 132 ± 7* 163 ± 12†




























Figure 1 Effects of MTX and enteral glutamine on intestinal injury score. The following parameters were investigated: (1) degeneration of
surface and crypt epithelium, (2) degeneration of villus structure and vacuolization in the surface epithelium (3) inflammatory cell infiltration and
bleeding and edema in the lamina propria. For each criterion, a score was given using a semiquantitative scale as follows: 0 = none, 1 =mild,
2 =moderate, 3 = severe, giving a maximum possible score of 9 for each segment. Values are mean ± SEM. CONTR-control, MTX-methotrexate,
GLN-glutamine. *P < 0.05 MTX and MTX-GLN vs CONTR rats. †P < 0.05 MTX-GLN vs MTX rats.
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Treatment of MTX rats with glutamine (Group D) re-
sulted in a significant increase in ileal TLR-4 mRNA
(60% increase, p < 0.05), ileal MyD88 mRNA (two-fold
decrease, p < 0.05) and ileal TRAF 6 mRNA expression
(two-fold decrease, p < 0.05) compared to MTX-rats
(Group C). MTX-GLN rats also showed a trend toward
an increase in TLR4 and MyD88 mRNA levels inTable 2 Effect of MTX and glutamine on microscopic intestina
Parameters/Groups CONTR
Villus height (μm)
Jejunum 461 ± 16
Ileum 304 ± 26
Crypt depth (μm)
Jejunum 184 ± 7
Ileum 157 ± 7
Cell proliferation (BrdU positive cells/10 crypts)
Jejunum 158 ± 9
Ileum 165 ± 14
Cell apoptosis (apoptotic cells/10 villi)
Jejunum 0.7 ± 0.2
Ileum 0.3 ± 0.05
CONTR-control, GLN-glutamine, MTX-methotrexate.
*P < 0.05 vs control, †P < 0.05 MTX-GLN vs MTX.jejunum; however, this trend did not achieve statistical
significance.
Expression of TLR-4 and MyD88 proteins
Western blot analysis confirmed the changes in TLR-4
and MyD88 (Figure 3). A significant decrease in TLR-4
protein expression in jejunum (7-fold decrease, p < 0.05)
and ileum (7-fold decrease, p < 0.05) and MyD88 proteinl parameters, cell proliferation and apoptosis
CONTR-GLN MTX MTX-GLN
460 ± 40 246 ± 11* 281 ± 14*†
294 ± 30 192 ± 17* 255 ± 11*†
148 ± 18 105 ± 8* 138 ± 10*†
131 ± 9 102 ± 3* 136 ± 13*†
163 ± 13 132 ± 4* 147 ± 5†
189 ± 25 129 ± 4* 152 ± 5†
0.9 ± 0.26 1.45 ± 0.23* 1.23 ± 0.23
0.5 ± 0.14 1.44 ± 0.13* 0.85 ± 0.26*†









































Figure 2 Evolution of mRNA expression levels of TLR4, MYD 88 and TRAF6 from the ileum of MTX and glutamine treated rats over
72 h. RNA was isolated from the ileum of rats subjected to MTX alone or to glutamine supplementation for 72 h. Real time PCR analysis was
performed to determine the expression level of TLR4, MYD 88 and TRAF6 mRNA comparing control, MTX with glutamine-fed rats. Values are
mean ± SEM. CONTR-control, MTX-methotrexate, GLN-glutamine. *P < 0.05 MTX and MTX-GLN vs CONTR rats. †P < 0.05 MTX-GLN vs MTX rats.
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ileum (30% decrease, p < 0.05) was found in MTX rats
(Group C) compared to control animals (Group A).
Treatment of MTX -rats with glutamine (Group D) re-
sulted in significant increase in TLR-4 protein in ileum
(two-fold, p < 0.05) and MyD88 protein in jejunum (90%,
p < 0.05) and ileum (two-fold, p < 0.05) compared to
MTX animals (Group C).
Immunohistochemistry for TLR-4 and TRAF6 expression
Expression of TLR4 and TRAF6 (Figure 4) in rat intes-
tinal tissues was also investigated in control, CONTR-
GLN, MTX and MTX-GLN animals using immunohis-
tochemistry. In control and CONTR-GLN rat intestinal
tissues, both TLR4 and TRAF6 expression stained with a
stronger intensity along the entire villus-crypt axis.
TLR4 and TRAF 6 were expressed on intraepithelial
lymphocytes and lymphocytes in the submucosa. In
addition, weak positive staining was observed in the
crypt region. Treatment of control animals with glutam-
ine (Group B) resulted in a trend toward increase in the
number of TLR-4 positive cells in jejunum as well as in
the number of TRAF-6 positive cells in jejunum and
ileum compared to control animals; however, this trend
was not statistically significant. MTX-induced intestinal
damage (Group C) was associated with a significant de-
crease in TLR-4 staining in jejunum (145 ± 17 vs 198 ±
11 positive cells/10 villi, p < 0.05) and ileum (164 ± 17 vs299 ± 11 positive cells/10 villi, p < 0.05) as well as in TRAF-
6 staining in jejunum (two-fold decrease, p < 0.05) and
ileum (161 ± 18 vs 210 ± 5 positive cells/10 villi, p < 0.05)
compared to control animals (Group A). Treatment of
MTX animals with glutamine diminished this inhibitory
effect of MTX on TLR-4 and TRAF-6 expression. MTX-
GLN animals (Group D) demonstrated a significant in-
crease in TLR-4 staining in jejunum (191 ± 10 vs 145 ±
17 positive cells/10 villi, p < 0.05) and ileum (204 ± 13 vs
164 ± 17 positive cells/10 villi, p < 0.05) as well as in
TRAF-6 staining in jejunum (215 ± 20 vs 138 ± 7 posi-
tive cells/10 villi, p < 0.05) and ileum (207 ± 29 vs 161 ±
18 positive cells/10 villi, p < 0.05) compared to MTX an-
imals (Group C).
Discussion
Mucositis is an important side effect of methotrexate
therapy for which there is no definitive prophylaxis or
treatment. This is due in part to the lack of understanding
of its pathogenesis and its impact on intestinal structure
and function. Over the last decades, significant progress
has been made in understanding the underlying mecha-
nisms of mucositis development. The pathobiology of mu-
cositis is complex and includes up-regulation of a range of
stress response cytokines and subsequent activation of
mitogen activated protein kinase (MAPK) signaling, nu-
clear factor κB (NFκB) signalling, Fos/Jun signalling and



























































CONTR CONTR-GLN MTX MTX-GLN
Figure 3 Expression of TLR4 and MyD 88 proteins in the jejunum and ileum. Tissue lysates were prepared for Western blot analysis and
50 μg of total protein were loaded and immunoblotted with anti- TLR4 and MyD 88 and TRAF6 antibodies, with tubulin as a loading control. Top:
a typical blot. Bottom: relative densitometric values are means ± SE. MTX rats demonstrated a significant decrease in TLR-4 and MyD88 expression
in jejunum and ileum compared to control animals. Protein expression of TLR-4 and MyD88 increased following glutamine administration.
CONTR-control, MTX-methotrexate, GLN-glutamine. *P < 0.05 MTX and MTX-GLN vs CONTR rats. †P < 0.05 MTX-GLN vs MTX rats.
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namely: initiation, which encompasses the primary
damage occurring following administration of cytotoxic
chemotherapy; message generation, involving the up-
regulation of transcription factors including NFκB,
MAPK, matrix metalloproteinases and subsequent acti-
vation of cytokine and stress response genes; signalling
and amplification producing proteins such as tumour
necrosis factor, interleukin-1β and interleukin-6 which
cause direct tissue damage and provide positive feed-
back to amplify the process; ulceration, which resuls in
painful ulcers, bacterial infiltration and an influx of
macrophages and other inflammatory cells and finally
healing, which spontaneously occurs upon cessation of
chemotherapy [11].
Possible mediators of mucositis which have not been
well studied are related to toll-like receptor signaling.TLR signaling has been shown to function in several of
the pathways which mediate mucositis development and
tissue injury in general. Therefore, TLRs deserve careful
consideration as possible mediators of chemotherapy-
induced mucositis. Toll-like receptors are an ancient
conserved receptor family that regulate antimicrobial
host defense in plants, invertebrates, and mammals [21].
Individual TLRs recognize distinct pathogen-associated
molecular patterns (PAMPs) that have been evolutionar-
ily conserved in specific classes of microbes. Interaction
of PAMPs with TLRs triggers a complex signaling path-
way that leads to the activation of the immune system.
There are more than 10 identified members of the TLR
family, with well-defined specificities to various compo-
nents of bacteria, viruses, and fungi [22]. The best char-
acterized member of this family is toll-like receptor 4






































CONTR CONTR-GLN MTX MTX-GLN
Figure 4 Immunohistochemical localization of TLR4 and TRAF6 in jejunal and ileal tissues. Magnification is 200. TLR4 and TRAF 6 were
expressed on intraepithelial lymphocytes and lymphocytes in submucosa. In addition weak positive staining was observed in the crypt region.
MTX-induced damage was associated with decreased TLR4 and TRAF6 staining. The number of TLR4 and TRAF6 positive cells increased significantly
following glutamine administration. CONTR-control, MTX-methotrexate, GLN-glutamine. *P < 0.05 MTX and MTX-GLN vs CONTR rats. †P < 0.05
MTX-GLN vs MTX rats.
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component that can elicit cellular responses. TLR-4 is
responsible for the recognition of bacterial endotoxin or
LPS and for initiation of the gram-negative bacillary sep-
tic shock syndrome [23,24]. Interaction between LPS
and TLR-4 leads to formation of an LPS signaling com-
plex consisting of surface molecules, such as CD14 and
MD2, as well as intracellular adaptor molecules, includ-
ing myeloid differentiation primary response gene 88
(MyD88), TNF-α receptor association factor 6 (TRAF6),
and activation of transcription factors, such as nuclear
factor κB (NFκB), which then induce the activation of
the inflammatory genes, such as tumor necrosis factor-α,
interleukin (IL)-1, IL-6, and IL-8 [5].
Epithelial cells of the gastrointestinal tract (GIT) undergo
continuous renewal. The process of cell turnover is tightly
regulated by mucosal as well as submucosal signalling in
order to maintain homeostasis and to compensate for dis-
turbances which may occur in the GIT. The distribution
and expression of TLRs in the basement membrane plays
a predominant role in regulating epithelial cell kinetics.
Therefore, it is important that TLRs levels are continu-
ously regulated to achieve a balance in tissue degradation
and fibrogenesis. Furthermore, a skewed level of tissue
TLRs has been implicated in the development of acute
and chronic intestinal diseases.
The TLR signaling following chemotherapy has not re-
ceived a great deal of attention. Previous studies have
shown a role for ROS and the pro-inflammatory cyto-
kines TNF and IL-1β in the message generation phase ofmucositis [25] and in the induction of TLR signaling
[26], separately, with no studies documenting a direct re-
lationship between TLR signaling and the development
of intestinal mucositis.
Glutamine is a non-essential amino acid which plays
an important role in many physiologic and biologic pro-
cesses. Growing evidence suggests that glutamine is an
important nutrient for rapidly dividing cells such as
those from the immune system and the gut [12]. We
have shown that treatment with oral glutamine prevents
mucosal injury and improves intestinal recovery follow-
ing MTX- injury in the rat [14]. In this other experi-
ment, we demonstrated a correlation between gut
trophic effects of glutamine and its stimulating effect on
TLR signaling during lipopolysaccharide endotoxemia in
a rat [15].
We hypothesized in the present study that this TLR4
signaling is involved during MTX-induced mucositis and
that glutamine could prevent intestinal mucosal injury
or/and improve intestinal recovery by affecting this
pathway. Our data has shown that a single dose of MTX
can cause a severe mucosal injury in the small bowel.
This is evident from the increased intestinal injury score.
Histologically, MTX-animals exhibited degeneration and
shortening of the villus length, severe villous epithelial
atrophy, significant loss of crypt architecture, signs of
crypt remodeling, and polymorphonuclear leukocyte in-
filtration in the lamina propria. In addition, MTX rats
showed intestinal mucosal hypoplasia. The observed de-
creased bowel and mucosal weight, decreased mucosal
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this conclusion. As a folic acid analogue, the action of
MTX primarily is to inhibit DNA synthesis by binding
to the enzyme dihydrofolate reductase. This leads to an
inhibition of proliferation in the crypts of the small in-
testine. Our data support this concept. Mucosal DNA
content as well as enterocyte proliferation index decreased
significantly in both jejunum and ileum following MTX
administration. Cell death via apoptosis increased signifi-
cantly in intestinal mucosa after MTX administration.
The loss of small intestinal epithelial cells leading to vil-
lous atrophy caused by MTX has been well described and
has been appreciated since the 1970s [27,28].
We found that administration of MTX was associated
with down-regulation of TLR-4 Myd88 and TRAF-6
mRNA expression in the jejunal and ileal mucosa. The
elevation of TLR-4 and Myd88 mRNA expression in the
ileum was found to be statistically significant. Changes
in protein levels were in agreement with mRNA expres-
sion. Both TLR-4 and Myd88 protein levels were signifi-
cantly down-regulated in MTX-treated rats compared to
control animals. The down-regulation expression of
TLR-4, Myd88 and TRAF-6 mRNA and protein expres-
sion were poorly correlated with severe mucositis, which
leads to induction of inflammatory cytokines such tumor
necrosis factor- α, IL-1, and IL-6; and, therefore, cannot
explain the developed widespread intestinal mucosal in-
jury. Previous imunohistochemical techniques have shown
that TLR4 is expressed at low levels by intraepithelial cells
in normal human colon tissues and predominantly in the
crypt epithelial cells [29,30]. In the current study, both
TLR4 and TRAF6 expressions stained with a stronger
intensity along the entire villus-crypt axis and were
expressed on intraepithelial lymphocytes and lymphocytes
in submucosa. In addition, weak positive staining was ob-
served in the crypt region. MTX-induced intestinal dam-
age was associated with a significant decrease in TLR-4
and TRAF-6 staining in jejunum and ileum compared to
control animals. These changes were in agreement with
changes in mRNA and protein levels. Since TLR4 signal-
ing is pro-inflammatory as well as administration of MTX
causes inflammatory response, it should be emphasized
that the down-regulation of components of the TLR sig-
naling cascade by MTX is presumably compensatory.
Such compensation mechanisms are common, activated
receptors mediate their own downregulation to limit/stop
the response to the stimulus.
We demonstrated previously the beneficial effects of
glutamine on methotrexate induced mucositis [15]; how-
ever, the exact mechanism of this positive effect remains
unclear. Consistent with these data, in the current study
enteral glutamine produced various beneficial effects.
The results of this study have shown that glutamine
given during 72 hours to control animals did not significantlychange intestinal mucosal parameters. However, pretreat-
ment with glutamine protected the intestinal mucosa from
damage caused by MTX. 80% of rats showed a significant
decrease in intestinal mucosal injury grade compared to
MTX animals, suggesting lesser degree of intestinal dam-
age. In addition, exposure to enteral glutamine accelerated
intestinal mucosal repair and enhanced enterocyte turn-
over. This is evident from the significant increase in bowel
and mucosal weight, increased DNA content and in-
creased villus height and crypt depth in this model. Treat-
ment with glutamine led to a rapid increase in the uptake
of bromdioxyuridine (BrdU) and the size of the prolifera-
tive compartment in the crypts. After exposure to glutam-
ine supplementation, an abnormally “rich” supply of
glutamine entering the small intestine might directly
stimulate mucosal hyperplasia. The epithelial cells lining
the intestinal canal probably use this amino acid for their
own nutrition. The increased absorption of glutamine
from the lumen may also stimulate the release and circu-
lation of enteric hormones which have trophic effects on
small bowel mucosa. An increased cell proliferation rate
was accompanied by increase in villus height, suggesting
an increased absorptive surface area. Increased cell pro-
liferation following glutamine administration was ac-
companied by decreased cell apoptosis. The specific
mechanism for the apparent anti-apoptotic effects of
glutamine has not yet been elucidated fully. Glutamine
may attenuate the enterocyte injury that precedes apop-
tosis, possibly as a membrane stabilizer or as a free-
radical scavenger, thereby preventing or delaying the
initiation of the apoptotic cascade. Alternatively, glu-
tamine may act intracellularly to alter the expression of
genes related to apoptosis or interfere with specific cas-
pase functions.
Treatment with glutamine in the current study attenu-
ated the inhibitory effect of MTX on TLR-4 signaling.
MTX-GLN rats demonstrated a significant increase in
ileal TLR-4 mRNA, MyD88 mRNA and TRAF 6 mRNA
expression compared to MTX-rats, which was correlated
with a trend toward increase in TLR-4 and MyD88 pro-
tein, and with the increased number of TLR-4 and
TRAF-6 positive cells (by immunohistochemistry). These
findings suggest that glutamine stimulates TLR signaling
pathways, which is in agreement with other experiments.
It has been reported that TLR2 and TLR4 expression is
up-regulated under inflammatory conditions [31], which
could provide a mechanism for certain inflammatory
diseases of the intestine. Indeed, there is a report of in-
creased TLR4 expression in the intestinal epithelium of
patients with Crohn’s disease and ulcerative colitis [32].
Whether TLR4 expression is a cause or a result of the
disease is unclear, but it does underscore the importance
of the gastrointestinal epithelium in preventing excessive
and uncontrolled inflammation. Current data suggests
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cosa during chemotherapy-induced mucositis on both
leukocytes and mucosal epithelial cells while serving to
modulate leukocyte-epithelial interactions. It should be
emphasized that aberrant TLR-4 expression may play an
important role in the loss of tolerance to the enteric
bacteria during chemotherapy-induced mucositis. Glu-
tamate, by increasing expression of components of the
TLR signaling pathway, would be expected to amplify
the inflammatory response and further increase damage
tissue. That it has the opposite effect suggests that glu-
tamate may be acting independently of TLR signaling.
The mechanism of the positive effect of glutamine on
gut barrier function is poorly understood. Recent evidence
suggests that glutamine prevents MTX-induced gut bar-
rier disruption by regulating occludin and claudin-1 prob-
ably through erk and NF-κB pathways [33]. Since TLR4-
MyD88/Mal-NF-kB signaling axis plays an important role
in gut barrier function, further experiments are required
to understand crosstalk between TLR-signaling and
NF-kB-signaling during chemotherapy-induced mucositis.
In summary, methotrexate inhibits TLR-4 signaling
pathways. Glutamine improves intestinal recovery and
attenuates this inhibitory effect. The positive effect of
glutamine on intestinal structure and gut barrier func-
tion in intestinal mucositis may be considered as a
mechanism by which immunonutrition helps in the re-
covery of oncologic patients receiving chemotherapy.
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